Top of the morning to you. And we hope it is a fine one. The skies are overcast here on the Pharmalot corporate campus, but our spirits remain sunny. As the Morning Mayor would say: 'Every brand new day should be unwrapped like a precious gift.' So go ahead and tug on the ribbon. And while you do that, please enjoy a few items from around the world. Have a great day, everyone...
Hep C Drugs Under Development Garner Upbeat Reviews (Los Angeles Times)
Glaxo Paid $85M To Doctors Last Year (Reuters)
Merck Paid $20M To Docs For Speaking Fees Last Year (Dow Jones)
Lundbeck Will Not Restrict Sales Of Execution Drug (Associated Press)
Valeant May Boost Cephalon Offer If Given Books (Winnipeg Free Press)
EU Approves Glaxo And Valeant Epilepsy Drug (Pharma Times)
1 Comment
Is the Glaxo/Valeant add-on epilepsy drug Potiga (ezogabine? FDA approved now, I think) or Trobalt (retigabine? Now approved in the EU?) Was it rebranded? Curious what sets it apart from gabapentin or pregabalin or any of the other add-on treatments available, aside from the urinary and cardiac issues.